All the Drug Class Drugs
Radio-Pharmaceutical. Lutetium [177Lu] Oxodotreotide 600 MBq/mL 7,400 MBq / 12.5 ml. VIAL (sol. for IV infusion):1X 12.5 ml (7,400 MBq). Recomm. dose: 4 vials at interval of 8 weeks between each, can be ext. to 16 weeks. See lit.
Tmt. of unresect. or metast., progr., well diff. (G1 and G2), somatost. recept-posit. gastroenteropancr. neuroendocr. tumors (GEP-NETs) in adults.
C/I: Hypersens. Pregnancy or susp. pregn.
Renal fail. (creatinine clear. <30 mL/min)
Radio-Pharmaceutical. Lutetium (177Lu) Oxodotreotide 370 MBq/ml. VIAL (sol. for infus.): 1. The recomm. tmt. regimen of Lutathera in adult. consists of 4 infus. of 7,400 MBq each. The recom. interval betwn. each admin. is 8 wks. which could be extended up to 16 wks. in case of dose modif. toxic. (DMT).
For renal protect. purpose, an amino acid sol. must be admin. IV during 4 hrs. The infus. of the amino acid sol. should start 30 min. prior to start of Lutetium (177LU) Oxodotreotide infus. See lit.
Tmt. of unresect. / metastat., progres., well different. (G1& G2), somatostatin recept. posit. gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult.
C/I: Hypersens. to the active subst. Establish./suspect. pregn. or when pregn. has not been exclud. Renal fail. with Cr/Cl < 30 mL/min.
Radio-Pharmaceutical. Radium-223 Dichloride 1100 kBq/ml. VIAL (sol. for inj.): 6 ml (6.0 MBq
radium-223 dichloride at the ref. date)
50 kBq per kg BDW., given at 4 week
interv. for 6 inj.
Dose must be administ./adjust. individ.
by a radiother. special.
Tmt. of adult. with castrat.-resist. prost.
cancer, sympt. bone metast. and no
known visc. metastases.
C/I: Not known.
